Related Experiment Video
Updated: Feb 28, 2026
08:15
Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
Published on: August 15, 2025
1.1K
Changes in metformin use in chronic kidney disease
1Division of Nephrology, Kaiser Permanente, Southern California Permanente Medical Group, Fontana, CA, USA.
Clinical Kidney Journal
|June 16, 2017
Summary
Metformin, a key diabetes drug, can now be used more widely in patients with reduced kidney function. This expands treatment options and lowers healthcare costs, benefiting many.
Area of Science:
- Endocrinology
- Nephrology
- Cardiovascular Medicine
Background:
- Metformin is a widely used antidiabetic medication.
- It is the only antidiabetic drug proven to reduce cardiovascular mortality in type 2 diabetes.
- Fear of lactic acidosis and FDA warnings have limited its use in patients with chronic kidney disease.
Purpose of the Study:
- To review the updated guidelines and evidence supporting expanded metformin use in patients with reduced kidney function.
- To highlight the benefits of metformin, including cardiovascular protection, cost-effectiveness, and impact on obesity and hypoglycemia.
Main Methods:
- Review of current clinical guidelines regarding metformin use in diabetic patients with varying degrees of kidney function.
- Analysis of evidence supporting the safety and efficacy of metformin in patients with chronic kidney disease.
- Examination of the economic and public health implications of expanded metformin use.
Main Results:
- Updated guidelines now support increased metformin use in patients with lower glomerular filtration rates.
- There is a shift towards assessing kidney function beyond serum creatinine levels.
- The US FDA is updating labeling to reflect recommendations for using metformin in patients with significantly reduced kidney function.
Conclusions:
- Expanded metformin use in patients with reduced kidney function is supported by current evidence and guidelines.
- This change allows more patients with type 2 diabetes and kidney disease to benefit from metformin's cardiovascular protective effects.
- Wider metformin adoption can improve healthcare costs, aid in obesity management, and simplify type 2 diabetes treatment.
More Related Videos
Related Concept Videos
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
284
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
284
01:18Chronic Kidney Disease IV: Nursing Management
485
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
485
01:28Chronic Kidney Disease III: Interprofessional Care
529
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
529
01:11Renal Failure: Dose Adjustments
537
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
537
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
283
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
283
01:24Chronic Kidney Disease II: Clinical Manifestations
801
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
801